Santarus Downgraded by Leerink Swann to “Market Perform” (SNTS)
Santarus (NASDAQ:SNTS) was downgraded by equities researchers at Leerink Swann from an “outperform” rating to a “market perform” rating in a research report issued on Thursday, TheFlyOnTheWall.com reports. They currently have a $26.00 price target on the stock. Leerink Swann’s price target suggests a potential upside of 3.05% from the company’s current price. The analysts noted that the move was a valuation call.
A number of other analysts have also recently weighed in on SNTS. Analysts at JMP Securities raised their price target on shares of Santarus from $27.00 to $31.00 in a research note to investors on Wednesday, August 7th. Separately, analysts at Zacks downgraded shares of Santarus from an “outperform” rating to a “neutral” rating in a research note to investors on Thursday, July 25th. They now have a $27.80 price target on the stock. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Santarus in a research note to investors on Wednesday, July 17th. They now have a $24.00 price target on the stock.
Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $25.63.
Shares of Santarus (NASDAQ:SNTS) traded down 3.09% during mid-day trading on Thursday, hitting $24.45. The stock had a trading volume of 992,411 shares. Santarus has a 52-week low of $6.01 and a 52-week high of $28.10. The stock’s 50-day moving average is $24.82 and its 200-day moving average is $21.3. The company has a market cap of $1.623 billion and a P/E ratio of 17.58.
Santarus (NASDAQ:SNTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.94 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.18 by $0.76. The company had revenue of $89.40 million for the quarter, compared to the consensus estimate of $82.90 million. During the same quarter in the prior year, the company posted $0.05 earnings per share. The company’s quarterly revenue was up 89.4% on a year-over-year basis. Analysts expect that Santarus will post $1.26 EPS for the current fiscal year.
In other Santarus news, Director Kent Snyder sold 7,500 shares of Santarus stock on the open market in a transaction dated Thursday, August 15th. The shares were sold at an average price of $25.89, for a total transaction of $194,175.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Santarus, Inc (NASDAQ:SNTS) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.